Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CABA |
---|---|---|
09:32 ET | 6501 | 13.23 |
09:34 ET | 2800 | 13.33 |
09:36 ET | 3314 | 13.385 |
09:38 ET | 200 | 13.41 |
09:39 ET | 3900 | 13.38 |
09:41 ET | 965 | 13.39 |
09:43 ET | 3395 | 13.375 |
09:45 ET | 4200 | 13.29 |
09:48 ET | 200 | 13.335 |
09:50 ET | 8750 | 13.285 |
09:52 ET | 6124 | 13.3 |
09:54 ET | 502 | 13.3 |
09:56 ET | 650 | 13.3 |
09:57 ET | 3194 | 13.42 |
09:59 ET | 1726 | 13.41 |
10:01 ET | 1641 | 13.41 |
10:03 ET | 1097 | 13.405 |
10:06 ET | 2328 | 13.39 |
10:08 ET | 17853 | 13.43 |
10:10 ET | 4998 | 13.46 |
10:12 ET | 901 | 13.5 |
10:14 ET | 6310 | 13.58 |
10:15 ET | 4604 | 13.51 |
10:17 ET | 2357 | 13.38 |
10:19 ET | 845 | 13.39 |
10:21 ET | 2989 | 13.37 |
10:24 ET | 1510 | 13.328 |
10:26 ET | 376 | 13.31 |
10:28 ET | 568 | 13.29 |
10:30 ET | 550 | 13.27 |
10:32 ET | 2500 | 13.285 |
10:33 ET | 200 | 13.285 |
10:35 ET | 700 | 13.285 |
10:37 ET | 1901 | 13.29 |
10:39 ET | 700 | 13.305 |
10:42 ET | 400 | 13.275 |
10:44 ET | 400 | 13.27 |
10:46 ET | 100 | 13.255 |
10:48 ET | 2200 | 13.265 |
10:50 ET | 1377 | 13.26 |
10:51 ET | 1987 | 13.195 |
10:53 ET | 3125 | 13.2608 |
10:55 ET | 439 | 13.26 |
10:57 ET | 1441 | 13.29 |
11:00 ET | 1300 | 13.33 |
11:02 ET | 700 | 13.32 |
11:04 ET | 3100 | 13.3 |
11:06 ET | 800 | 13.23 |
11:08 ET | 1107 | 13.2 |
11:09 ET | 467 | 13.16 |
11:11 ET | 2012 | 13.08 |
11:13 ET | 3665 | 12.97 |
11:15 ET | 1994 | 12.8905 |
11:18 ET | 3986 | 12.96 |
11:22 ET | 1400 | 12.965 |
11:24 ET | 619 | 12.96 |
11:26 ET | 2122 | 12.955 |
11:27 ET | 200 | 12.955 |
11:29 ET | 1088 | 12.95 |
11:31 ET | 3500 | 12.97 |
11:33 ET | 600 | 12.97 |
11:36 ET | 4296 | 12.98 |
11:38 ET | 2624 | 13.025 |
11:40 ET | 7715 | 13.13 |
11:42 ET | 3289 | 13.07 |
11:44 ET | 2088 | 13.06 |
11:45 ET | 993 | 13.055 |
11:47 ET | 2700 | 13.095 |
11:49 ET | 6565 | 13.205 |
11:51 ET | 6917 | 13.135 |
11:54 ET | 1796 | 13.15 |
11:58 ET | 833 | 13.12 |
12:00 ET | 6387 | 13.19 |
12:02 ET | 700 | 13.19 |
12:03 ET | 1200 | 13.25 |
12:05 ET | 400 | 13.255 |
12:07 ET | 3873 | 13.305 |
12:09 ET | 100 | 13.305 |
12:12 ET | 5234 | 13.34 |
12:14 ET | 500 | 13.35 |
12:16 ET | 300 | 13.34 |
12:18 ET | 1121 | 13.4 |
12:20 ET | 400 | 13.41 |
12:21 ET | 966 | 13.4 |
12:23 ET | 880 | 13.42 |
12:25 ET | 200 | 13.41 |
12:27 ET | 3341 | 13.385 |
12:30 ET | 1398 | 13.38 |
12:34 ET | 300 | 13.38 |
12:36 ET | 436 | 13.38 |
12:38 ET | 887 | 13.38 |
12:39 ET | 857 | 13.37 |
12:41 ET | 2426 | 13.35 |
12:43 ET | 2799 | 13.37 |
12:45 ET | 2820 | 13.41 |
12:48 ET | 1800 | 13.395 |
12:50 ET | 1941 | 13.37 |
12:52 ET | 500 | 13.355 |
12:54 ET | 3682 | 13.34 |
12:56 ET | 2200 | 13.34 |
12:57 ET | 198 | 13.34 |
12:59 ET | 1000 | 13.345 |
01:01 ET | 2421 | 13.32 |
01:03 ET | 2178 | 13.34 |
01:06 ET | 860 | 13.345 |
01:08 ET | 3363 | 13.36 |
01:10 ET | 200 | 13.3783 |
01:12 ET | 100 | 13.37 |
01:14 ET | 2575 | 13.37 |
01:15 ET | 2370 | 13.38 |
01:17 ET | 1400 | 13.39 |
01:19 ET | 600 | 13.39 |
01:21 ET | 800 | 13.4 |
01:24 ET | 1831 | 13.435 |
01:26 ET | 100 | 13.44 |
01:28 ET | 600 | 13.44 |
01:30 ET | 400 | 13.44 |
01:32 ET | 5030 | 13.42 |
01:33 ET | 1178 | 13.41 |
01:35 ET | 2700 | 13.44 |
01:37 ET | 4011 | 13.43 |
01:39 ET | 400 | 13.44 |
01:42 ET | 1126 | 13.44 |
01:44 ET | 300 | 13.44 |
01:46 ET | 2000 | 13.47 |
01:48 ET | 1200 | 13.45 |
01:50 ET | 2918 | 13.53 |
01:51 ET | 1679 | 13.515 |
01:53 ET | 1500 | 13.555 |
01:55 ET | 1511 | 13.55 |
01:57 ET | 3100 | 13.53 |
02:00 ET | 2517 | 13.5 |
02:04 ET | 1500 | 13.5326 |
02:06 ET | 1100 | 13.53 |
02:08 ET | 600 | 13.54 |
02:09 ET | 6014 | 13.54 |
02:11 ET | 6549 | 13.5 |
02:13 ET | 1485 | 13.53 |
02:15 ET | 200 | 13.53 |
02:18 ET | 700 | 13.53 |
02:20 ET | 6573 | 13.58 |
02:22 ET | 2769 | 13.58 |
02:24 ET | 1870 | 13.56 |
02:26 ET | 520 | 13.54 |
02:27 ET | 422 | 13.55 |
02:29 ET | 400 | 13.55 |
02:31 ET | 1317 | 13.53 |
02:33 ET | 6135 | 13.555 |
02:36 ET | 100 | 13.57 |
02:38 ET | 1200 | 13.58 |
02:40 ET | 3700 | 13.55 |
02:42 ET | 300 | 13.565 |
02:44 ET | 800 | 13.57 |
02:45 ET | 100 | 13.58 |
02:47 ET | 400 | 13.57 |
02:49 ET | 613 | 13.57 |
02:51 ET | 8456 | 13.51 |
02:54 ET | 1000 | 13.51 |
02:56 ET | 1200 | 13.53 |
02:58 ET | 3501 | 13.53 |
03:00 ET | 1443 | 13.52 |
03:02 ET | 306 | 13.52 |
03:03 ET | 100 | 13.52 |
03:05 ET | 1488 | 13.535 |
03:07 ET | 1057 | 13.52 |
03:09 ET | 2916 | 13.48 |
03:12 ET | 1200 | 13.48 |
03:14 ET | 1859 | 13.49 |
03:16 ET | 1693 | 13.52 |
03:18 ET | 1000 | 13.525 |
03:20 ET | 9509 | 13.465 |
03:21 ET | 2075 | 13.385 |
03:23 ET | 1502 | 13.34 |
03:25 ET | 6565 | 13.23 |
03:27 ET | 35060 | 13.265 |
03:30 ET | 2536 | 13.27 |
03:32 ET | 4876 | 13.32 |
03:34 ET | 6600 | 13.31 |
03:36 ET | 4057 | 13.275 |
03:38 ET | 6277 | 13.29 |
03:39 ET | 5628 | 13.28 |
03:41 ET | 4267 | 13.285 |
03:43 ET | 3735 | 13.27 |
03:45 ET | 5729 | 13.28 |
03:48 ET | 5078 | 13.26 |
03:50 ET | 8874 | 13.24 |
03:52 ET | 10808 | 13.175 |
03:54 ET | 9489 | 13.225 |
03:56 ET | 11302 | 13.24 |
03:57 ET | 14800 | 13.29 |
03:59 ET | 139851 | 13.32 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cabaletta Bio Inc | 642.6M | -8.1x | --- |
Hillevax Inc | 645.1M | -4.3x | --- |
Savara Inc | 649.3M | -13.7x | --- |
enGene Holdings Inc | 652.7M | -3.2x | --- |
Nuvation Bio Inc | 661.1M | -7.7x | --- |
ProKidney Corp | 623.8M | -4.8x | --- |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $642.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.46 |
EPS | $-1.65 |
Book Value | $4.94 |
P/E Ratio | -8.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.